FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Citation |
| Id | Citation-267246.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Citation 267246
version: 12; Last updated: 2025-10-13 12:34:35+0000
Profile: JournalArticleCitation
ArtifactPublicationStatus: Active
url: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
identifier: FEvIR Object Identifier/267246, https://pubmed.ncbi.nlm.nih.gov/11232013, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.46
version: 1.0.0-ballot3
title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
status: Active
date: 2026-02-10 14:00:26+0000
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| Citation Classification Type: fevir-platform-use (FEvIR Platform Use) | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2001-04-12
lastReviewDate: 2018-11-30
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2001-03-07 10:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2001-04-17 10:01:00+0000
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2001-03-07 10:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/11232013,https://doi.org/10.1210/jcem.86.1.7157Titles
Type Text Primary title Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Abstracts
Type Text Primary human use This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
relatesTo
type: Correction In
classifier: Published Erratum
citation:
J Clin Endocrinol Metab 2001 Apr;86(4):1659
relatesTo
type: Correction In
classifier: Published Erratum
citation:
J Clin Endocrinol Metab. 2002 Feb;2(1):iv.
publicationForm
publishedIn
type: Periodical
identifier: Print ISSN Type/0021-972X, ISOAbbreviation/J Clin Endocrinol Metab, ISSN Linking/0021-972X, Medline Title Abbreviation/J Clin Endocrinol Metab, NLM Unique ID/0375362
title: The Journal of clinical endocrinology and metabolism
publisherLocation: United States
citedMedium: Print
volume: 86
issue: 1
articleDate: 2001-01
pageString: 280-8
WebLocations
Classifier Url Abstract https://pubmed.ncbi.nlm.nih.gov/11232013/ classification
type: Publishing Model
classifier: Print
classification
type: Chemical
classifier: Blood Glucose, Hypoglycemic Agents, Thiazoles, Thiazolidinediones, Rosiglitazone
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Lebovitz HE
forenameInitials: HE
affiliation: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net
entry
contributor: Dole JF
forenameInitials: JF
entry
contributor: Patwardhan R
forenameInitials: R
entry
contributor: Rappaport EB
forenameInitials: EB
entry
contributor: Freed MI
forenameInitials: MI
entry
contributor: Rosiglitazone Clinical Trials Study Group
Generated Narrative: Practitioner #contributor0
name: H E Lebovitz
Generated Narrative: Practitioner #contributor1
name: J F Dole
Generated Narrative: Practitioner #contributor2
name: R Patwardhan
Generated Narrative: Practitioner #contributor3
name: E B Rappaport
Generated Narrative: Practitioner #contributor4
name: M I Freed
Generated Narrative: Organization #contributor5
name: Rosiglitazone Clinical Trials Study Group
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Blood Glucose
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: analysis
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Diabetes Mellitus, Type 2
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
Type Classifier is Major topic No component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes component
type: qualifier
classifier: physiopathology
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Double-Blind Method
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Female
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Hypoglycemic Agents
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Islets of Langerhans
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: physiopathology
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Rosiglitazone
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Single-Blind Method
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Thiazoles
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Thiazolidinediones
freeToShare: true
Components
Type Classifier qualifier is Major topic
FHIR
FHIRsmith{
"resourceType": "Citation",
"id": "267246",
"meta": {
"versionId": "12",
"lastUpdated": "2025-10-13T12:34:35.118Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"contained": [
{
"resourceType": "Practitioner",
"id": "contributor0",
"name": [
{
"family": "Lebovitz",
"given": [
"H E"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor1",
"name": [
{
"family": "Dole",
"given": [
"J F"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor2",
"name": [
{
"family": "Patwardhan",
"given": [
"R"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor3",
"name": [
{
"family": "Rappaport",
"given": [
"E B"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor4",
"name": [
{
"family": "Freed",
"given": [
"M I"
]
}
]
},
{
"resourceType": "Organization",
"id": "contributor5",
"name": "Rosiglitazone Clinical Trials Study Group"
},
{
"resourceType": "ArtifactAssessment",
"id": "meshHeading0",
"artifactReference": {
"reference": "#",
"type": "Citation"
},
"content": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000368",
"display": "Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000369",
"display": "Aged, 80 and over",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D001786",
"display": "Blood Glucose",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000032",
"display": "analysis"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D003924",
"display": "Diabetes Mellitus, Type 2",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000097",
"display": "blood"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000188",
"display": "drug therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000503",
"display": "physiopathology"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D004311",
"display": "Double-Blind Method",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D005260",
"display": "Female",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D006801",
"display": "Humans",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D007004",
"display": "Hypoglycemic Agents",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000009",
"display": "adverse effects"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D007515",
"display": "Islets of Langerhans",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000187",
"display": "drug effects"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000503",
"display": "physiopathology"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008297",
"display": "Male",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008875",
"display": "Middle Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000077154",
"display": "Rosiglitazone",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016037",
"display": "Single-Blind Method",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D013844",
"display": "Thiazoles",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000009",
"display": "adverse effects"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D045162",
"display": "Thiazolidinediones",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is Major topic"
}
]
}
]
}
]
}
],
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Citation/267246",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "267246",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "11232013"
},
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.4.642.40.44.15.46"
}
],
"version": "1.0.0-ballot3",
"title": "11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.",
"status": "active",
"date": "2026-02-10T14:00:26+00:00",
"author": [
{
"name": "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"publisher": "HL7 International / Clinical Decision Support",
"contact": [
{
"name": "HL7 International / Clinical Decision Support",
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext": [
{
"code": {
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "fevir-platform-use",
"display": "FEvIR Platform Use"
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "medline-base",
"display": "Medline Base",
"userSelected": false
}
]
}
}
],
"jurisdiction": [
{
"coding": [
{
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code": "001",
"display": "World"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate": "2001-04-12",
"lastReviewDate": "2018-11-30",
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "citation-source",
"display": "Citation Source"
}
]
},
"classifier": [
{
"text": "MEDLINE"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "medline-owner",
"display": "MEDLINE Citation Owner"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code": "NLM",
"display": "National Library of Medicine, Index Section",
"userSelected": false
}
]
}
]
}
],
"currentState": [
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "medline-medline",
"display": "Medline Citation Status of Medline"
}
]
},
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-publication-status-ppublish",
"display": "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate": [
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-pubmed",
"display": "PubMed Pubstatus of Pubmed"
}
]
},
"period": {
"end": "2001-03-07T10:00:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-medline",
"display": "PubMed Pubstatus of Medline"
}
]
},
"period": {
"end": "2001-04-17T10:01:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-entrez",
"display": "PubMed Pubstatus of Entrez"
}
]
},
"period": {
"end": "2001-03-07T10:00:00.000Z"
}
}
],
"citedArtifact": {
"identifier": [
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "11232013"
},
{
"system": "https://doi.org",
"value": "10.1210/jcem.86.1.7157"
}
],
"title": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/title-type",
"code": "primary",
"display": "Primary title"
}
]
}
],
"text": "Rosiglitazone monotherapy is effective in patients with type 2 diabetes."
}
],
"abstract": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type",
"code": "primary-human-use",
"display": "Primary human use"
}
]
}
],
"text": "This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions."
}
],
"relatesTo": [
{
"type": "correction-in",
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016425",
"display": "Published Erratum",
"userSelected": false
}
]
}
],
"citation": "J Clin Endocrinol Metab 2001 Apr;86(4):1659"
},
{
"type": "correction-in",
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016425",
"display": "Published Erratum",
"userSelected": false
}
]
}
],
"citation": "J Clin Endocrinol Metab. 2002 Feb;2(1):iv."
}
],
"publicationForm": [
{
"publishedIn": {
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/published-in-type",
"code": "D020492",
"display": "Periodical"
}
]
},
"identifier": [
{
"type": {
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code": "Print",
"display": "Print"
}
],
"text": "Print ISSN Type"
},
"system": "https://portal.issn.org",
"value": "0021-972X"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISOAbbreviation"
},
"system": "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value": "J Clin Endocrinol Metab"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISSN Linking"
},
"system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value": "0021-972X"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "Medline Title Abbreviation"
},
"system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value": "J Clin Endocrinol Metab"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "NLM Unique ID"
},
"system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value": "0375362"
}
],
"title": "The Journal of clinical endocrinology and metabolism",
"publisherLocation": "United States"
},
"citedMedium": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-medium",
"code": "print",
"display": "Print"
}
]
},
"volume": "86",
"issue": "1",
"articleDate": "2001-01",
"pageString": "280-8"
}
],
"webLocation": [
{
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code": "abstract",
"display": "Abstract"
}
]
}
],
"url": "https://pubmed.ncbi.nlm.nih.gov/11232013/"
}
],
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publishing-model",
"display": "Publishing Model",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "Print",
"display": "Print",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "chemical",
"display": "Chemical",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D001786",
"display": "Blood Glucose",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D007004",
"display": "Hypoglycemic Agents",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D013844",
"display": "Thiazoles",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D045162",
"display": "Thiazolidinediones",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.cas.org/support/documentation/chemical-substances",
"code": "05V02F2KDG",
"userSelected": false
},
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000077154",
"display": "Rosiglitazone",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
]
},
"artifactAssessment": [
{
"reference": "#meshHeading0",
"type": "ArtifactAssessment"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publication-type",
"display": "Publication type"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016430",
"display": "Clinical Trial",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016448",
"display": "Multicenter Study",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016449",
"display": "Randomized Controlled Trial",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "knowledge-artifact-type",
"display": "Knowledge Artifact Type",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
}
],
"artifactAssessment": [
{
"display": "Classifier added by Computable Publishing LLC"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "citation-subset",
"display": "Citation subset",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code": "IM",
"display": "IM",
"userSelected": false
}
]
}
]
}
],
"contributorship": {
"complete": true,
"entry": [
{
"contributor": {
"reference": "#contributor0",
"type": "Practitioner",
"display": "Lebovitz HE"
},
"forenameInitials": "HE",
"affiliation": [
{
"display": "Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net"
}
]
},
{
"contributor": {
"reference": "#contributor1",
"type": "Practitioner",
"display": "Dole JF"
},
"forenameInitials": "JF"
},
{
"contributor": {
"reference": "#contributor2",
"type": "Practitioner",
"display": "Patwardhan R"
},
"forenameInitials": "R"
},
{
"contributor": {
"reference": "#contributor3",
"type": "Practitioner",
"display": "Rappaport EB"
},
"forenameInitials": "EB"
},
{
"contributor": {
"reference": "#contributor4",
"type": "Practitioner",
"display": "Freed MI"
},
"forenameInitials": "MI"
},
{
"contributor": {
"reference": "#contributor5",
"type": "Organization",
"display": "Rosiglitazone Clinical Trials Study Group"
}
}
]
}
}
}